Pharmacogenomics: road to anticancer therapeutics nirvana?

被引：43
作者：
Desai, AA
Innocenti, F
Ratain, MJ
机构：
[1] Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA
来源：
ONCOGENE | 2003年 / 22卷 / 42期
关键词：
pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase;
D O I：
10.1038/sj.onc.1206958
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.
引用
收藏
页码：6621 / 6628
页数：8
相关论文
共 90 条
  • [1] Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity
    Acuña G.
    Foernzler D.
    Leong D.
    Rabbia M.
    Smit R.
    Dorflinger E.
    Gasser R.
    Hoh J.
    Ott J.
    Borroni E.
    To Z.
    Thompson A.
    Li J.
    Hashimoto L.
    Lindpaintner K.
    [J]. The Pharmacogenomics Journal, 2002, 2 (5) : 327 - 334
  • [2] EPIDERMAL GROWTH-FACTOR RECEPTORS
    ADAMSON, ED
    REES, AR
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 1981, 34 (03) : 129 - 152
  • [3] Akaba K, 1998, BIOCHEM MOL BIOL INT, V46, P21
  • [4] Akimoto T, 1999, CLIN CANCER RES, V5, P2884
  • [5] Ando Y, 2000, CANCER RES, V60, P6921
  • [6] RELATIONSHIP BETWEEN DEVELOPMENT OF DIARRHEA AND THE CONCENTRATION OF SN-38, AN ACTIVE METABOLITE OF CPT-11, IN THE INTESTINE AND THE BLOOD-PLASMA OF ATHYMIC MICE FOLLOWING INTRAPERITONEAL ADMINISTRATION OF CPT-11
    ARAKI, E
    ISHIKAWA, M
    IIGO, M
    KOIDE, T
    ITABASHI, M
    HOSHI, A
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (06): : 697 - 702
  • [7] Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
    Aschele, C
    Debernardis, D
    Casazza, S
    Antonelli, G
    Tunesi, G
    Baldo, C
    Lionetto, R
    Maley, F
    Sobrero, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1760 - 1770
  • [8] Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism?
    Beutler, E
    Gelbart, T
    Demina, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) : 8170 - 8174
  • [9] THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME
    BOSMA, PJ
    CHOWDHURY, JR
    BAKKER, C
    GANTLA, S
    DEBOER, A
    OOSTRA, BA
    LINDHOUT, D
    TYTGAT, GNJ
    JANSEN, PLM
    ELFERINK, RPJO
    CHOWDHURY, NR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) : 1171 - 1175
  • [10] BRUNO R, 2003, P ASCO, V22
123456789